September 29, 2025 — Leads & Copy — Datavault AI (NASDAQ:DVLT) is entering the biotech sector through a partnership with Scilex Holding Company, marking a significant step for its AI-driven data solutions. The collaboration brings $150 million in capital and access to a data analytics market. This partnership aims to address biotech’s data integrity challenges, using Datavault’s Information Data Exchange® to validate and secure data at the transaction level.
Datavault’s platform secures clinical trials, genomic research, and pharmaceutical supply chains, creating a foundation of trust for researchers, regulators, and pharmaceutical companies. By proving its platform in biotech, Datavault intends to expand into other sectors, addressing the growing global AI and data analytics markets.
Scilex’s investment signals the demand for Datavault’s technology, positioning it to capitalize on opportunities in genomics, clinical trial verification, and biofuels. Datavault’s entry into biotech serves as a proving ground and a launchpad for broader market penetration.
EMAIL contact for this release: info@hawkpointmedia.com
Source: Datavault AI
